"MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control." by John H. Sampson

Article

MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.

Journal of Clinical Oncology (2020)

John H. Sampson, Duke University
Achal Achrol, Loma Linda University Medical Center
Manish K. Aghi, University of California, San Francisco
Krystof Bankiewicz, Ohio State University
Martin Bexon, Medicenna Biopharma, Houston, TX;
Steven Brem, University of Pennsylvania
Andrew Jacob Brenner, University of Texas Health Science Center at San Antonio
Chandtip Chandhasin, Medicenna Biopharma, Houston, TX;
Sajeel A. Chowdhary, Boca Raton Regional Hospital
Melissa Coello, Medicenna Biopharma, Houston, TX;
Sunit Das, St. Michael's Hospital
Seunggu Jude Han, Oregon Health & Science University
Santosh Kesari, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence, Saint John’s Health Center, Santa Monica, CA;
Fahar Merchant, Suite 700, Toronto, ON, Canada;
Nina Merchant, Medicenna Biopharma, Houston, TX;
Dina Randazzo, Duke University
Michael A. Vogelbaum, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;
Frank Vrionis, Boca Raton Regional Hospital
Miroslaw Zabek, Mazovian Brodnowski Hospital, Warsaw, Poland;
Nicholas A. Butowski, University of California, San Francisco

Link

Disciplines

Publication Date

May 25, 2020

DOI

10.1200/JCO.2020.38.15_SUPPL.2513

Citation Information

John H. Sampson, Achal Achrol, Manish K. Aghi, Krystof Bankiewicz, et al.. "MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control." Journal of Clinical Oncology Vol. 38 (2020) p. 2513 - 2513
Available at: http://works.bepress.com/achalsingh-achrol/64/